3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor for Mechanistic and Translational Research

Executive Summary: 3-Aminobenzamide (PARP-IN-1) is a highly potent inhibitor of poly (ADP-ribose) polymerase (PARP), with an IC₅₀ of approximately 50 nM in CHO cell assays, and achieves >95% PARP inhibition at concentrations above 1 μM without significant cytotoxicity (APExBIO). Its specificity and solubility parameters enable robust assay design across oxidative stress and diabetic nephropathy models (PrecisionFDA). The compound has been shown to ameliorate diabetes-induced podocyte depletion and mesangial expansion in db/db mouse models (Grunewald et al., 2019). 3-Aminobenzamide supports studies into ADP-ribosylation, viral pathogenesis, and innate immunity by reliably inhibiting PARP activity in cell-based and biochemical workflows. APExBIO supplies this compound (SKU A4161) with validated storage and solubility data for reproducible research.

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes catalyzing the addition of ADP-ribose units to target proteins, a process known as ADP-ribosylation (Grunewald et al., 2019). Humans encode 17 PARPs, of which several modulate DNA repair, cellular stress responses, and innate immunity. PARP1 and PARP2, in particular, mediate DNA damage-induced signaling through poly-ADP-ribosylation (PARylation). Viral macrodomains counteract host PARP activity, emphasizing the importance of PARP inhibitors in dissecting host-pathogen interactions. 3-Aminobenzamide (PARP-IN-1) enables precise, reversible inhibition of PARP activity in cellular and in vivo models. This supports research into oxidative stress, endothelial dysfunction, diabetic nephropathy, and viral pathogenesis mechanisms (APExBIO).

Mechanism of Action of 3-Aminobenzamide (PARP-IN-1)

3-Aminobenzamide is a competitive inhibitor that targets the NAD⁺-binding site of PARP enzymes. By binding to this site, it prevents PARPs from catalyzing the transfer of ADP-ribose from NAD⁺ to substrate proteins (Grunewald et al., 2019). This inhibition disrupts PARylation-dependent signaling, attenuating DNA repair and stress response pathways.

• In CHO cell-based assays, 3-Aminobenzamide exhibits an IC₅₀ of approximately 50 nM for PARP inhibition (APExBIO).
• At concentrations >1 μM, it achieves over 95% inhibition of PARP activity without significant toxicity to mammalian cells.
• The compound is active against both PARP1 and PARP2, the principal poly-ADP-ribosylating enzymes in mammalian cells (Grunewald et al., 2019).
• PARP inhibition by 3-Aminobenzamide blocks the formation of poly (ADP-ribose) chains, preventing recruitment of DNA repair factors.

Evidence & Benchmarks

• 3-Aminobenzamide (PARP-IN-1) achieves an IC₅₀ of ~50 nM in CHO cell PARP inhibition assays (APExBIO).
• At ≥1 μM, it provides >95% inhibition of cellular PARP activity with minimal cytotoxicity (APExBIO).
• In models of oxidative stress, 3-Aminobenzamide improves endothelial function by enhancing acetylcholine-induced, endothelium-dependent, nitric oxide-mediated vasorelaxation following hydrogen peroxide exposure (APExBIO).
• In db/db mouse models of diabetic nephropathy, the compound ameliorates albuminuria, mesangial expansion, and podocyte depletion, demonstrating translational relevance (Grunewald et al., 2019).
• Pan-PARP inhibition, including by 3-Aminobenzamide, increases replication of macrodomain-mutant coronaviruses and reduces interferon production in primary macrophages (Fig 4, Grunewald et al., 2019).
• Solubility benchmarks: ≥23.45 mg/mL in water (ultrasonic), ≥48.1 mg/mL in ethanol (ultrasonic), ≥7.35 mg/mL in DMSO.
• Optimal storage: -20°C; long-term solution storage not recommended for stability (APExBIO).

This article extends previous summaries (PrecisionFDA, Sulfonhsssbiotin) by integrating updated benchmarks and clarifying translational limits in viral and nephropathy models.

Applications, Limits & Misconceptions

3-Aminobenzamide (PARP-IN-1) is widely used in:

• Cellular and in vitro PARP activity assays (e.g., CHO cells).
• Modeling oxidant-induced myocyte dysfunction during reperfusion studies.
• Endothelial function assays involving nitric oxide-mediated vasorelaxation after oxidative stress.
• Diabetic nephropathy research, especially for evaluating podocyte depletion and mesangial expansion in mouse models.
• Exploring viral pathogenesis, particularly for dissecting ADP-ribosylation’s role in innate immunity and interferon regulation (Grunewald et al., 2019).

Contrast: While this prior summary emphasizes specificity and reproducibility in oxidative stress models, the present article details benchmarks in viral pathogenesis and nephropathy workflows, clarifying utility boundaries.

Common Pitfalls or Misconceptions

• Not a pan-ADP-ribosylation inhibitor: 3-Aminobenzamide selectively inhibits PARP family enzymes, not other ADP-ribosyltransferases such as ARTCs or sirtuins (Grunewald et al., 2019).
• Not effective in all viral strains: Efficacy in modulating virus replication is specific to macrodomain-mutant strains; wild-type viruses with intact macrodomains may not be affected (Grunewald et al., 2019).
• Not recommended for diagnostic or medical use: This compound is for research use only and is not validated for diagnostic or therapeutic purposes (APExBIO).
• Stability limitations: Long-term storage of solutions can lead to degradation; always prepare fresh aliquots (APExBIO).
• Solubility depends on solvent and ultrasonic assistance: Maximum solubility is achieved with ultrasonic agitation in water or ethanol.

Workflow Integration & Parameters

• Preparation: Dissolve 3-Aminobenzamide to ≥23.45 mg/mL in water, ≥48.1 mg/mL in ethanol, or ≥7.35 mg/mL in DMSO using ultrasonic assistance.
• Assay Design: Use at 50 nM–1 μM in CHO cell or similar cellular assays to achieve maximal PARP inhibition with low cytotoxicity.
• Controls: Include vehicle and positive controls for PARP activity and cytotoxicity.
• Storage: Store solid at -20°C. Prepare fresh solutions for each experiment. Avoid repeated freeze-thaw cycles (APExBIO).
• Shipping: APExBIO ships under Blue Ice conditions for stability.
• Regulatory: For research use only; not for diagnostics or in vivo therapy.

Compared to prior workflow guides, this article provides updated solubility and handling parameters validated for contemporary disease models.

Conclusion & Outlook

3-Aminobenzamide (PARP-IN-1) from APExBIO remains a gold standard for potent, specific, and reproducible inhibition of poly (ADP-ribose) polymerases in cellular, biochemical, and animal models (APExBIO). Its validated nanomolar potency, high solubility, and low toxicity profile support advanced research in oxidative stress, endothelial biology, diabetic nephropathy, and host-pathogen interactions. As understanding of PARP biology expands, 3-Aminobenzamide will continue to provide mechanistic and translational insights—provided researchers respect its boundaries of specificity and stability. For full technical data and ordering, see the official A4161 product page.